NCT03929601 — National Institute of Diabetes and… cancer immunotherapy trial
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Registry record
| Registry ID | NCT03929601 ↗ |
|---|---|
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Collaborators | National Institutes of Health (NIH) |
| Phase | Phase 2 |
| Status | Active Not Recruiting |
| Indication | Type 1 Diabetes Mellitus |
| Enrollment | 74 participants (target) |
| Start date | 2023-10-30 |
| Primary completion | 2027-03-31 (est.) |
| Last registry update | 1 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03929601), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
FAQ
What phase is NCT03929601?
NCT03929601 (Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes) is registered on ClinicalTrials.gov as Phase 2, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Is NCT03929601 recruiting?
As of the 2026-09-01 registry update, NCT03929601 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03929601?
The lead sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Collaborators: National Institutes of Health (NIH).
What condition does NCT03929601 study?
The registered condition is Type 1 Diabetes Mellitus. Primary completion is listed as 2027-03-31 (estimated).
Are results available for NCT03929601?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03929601.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.